JP2018515460A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515460A5
JP2018515460A5 JP2017555626A JP2017555626A JP2018515460A5 JP 2018515460 A5 JP2018515460 A5 JP 2018515460A5 JP 2017555626 A JP2017555626 A JP 2017555626A JP 2017555626 A JP2017555626 A JP 2017555626A JP 2018515460 A5 JP2018515460 A5 JP 2018515460A5
Authority
JP
Japan
Prior art keywords
effective amount
use according
pain
inflammatory
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017555626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515460A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/031668 external-priority patent/WO2016183097A1/en
Publication of JP2018515460A publication Critical patent/JP2018515460A/ja
Publication of JP2018515460A5 publication Critical patent/JP2018515460A5/ja
Priority to JP2021158088A priority Critical patent/JP2022008597A/ja
Pending legal-status Critical Current

Links

JP2017555626A 2015-05-11 2016-05-10 炎症または神経障害性疼痛を処置する方法 Pending JP2018515460A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021158088A JP2022008597A (ja) 2015-05-11 2021-09-28 炎症または神経障害性疼痛を処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562159770P 2015-05-11 2015-05-11
US62/159,770 2015-05-11
US201662297670P 2016-02-19 2016-02-19
US62/297,670 2016-02-19
PCT/US2016/031668 WO2016183097A1 (en) 2015-05-11 2016-05-10 Methods of treating inflammation or neuropathic pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021158088A Division JP2022008597A (ja) 2015-05-11 2021-09-28 炎症または神経障害性疼痛を処置する方法

Publications (2)

Publication Number Publication Date
JP2018515460A JP2018515460A (ja) 2018-06-14
JP2018515460A5 true JP2018515460A5 (https=) 2019-06-13

Family

ID=57249499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017555626A Pending JP2018515460A (ja) 2015-05-11 2016-05-10 炎症または神経障害性疼痛を処置する方法
JP2021158088A Pending JP2022008597A (ja) 2015-05-11 2021-09-28 炎症または神経障害性疼痛を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021158088A Pending JP2022008597A (ja) 2015-05-11 2021-09-28 炎症または神経障害性疼痛を処置する方法

Country Status (14)

Country Link
US (3) US10450302B2 (https=)
EP (1) EP3294731A4 (https=)
JP (2) JP2018515460A (https=)
KR (1) KR20180004263A (https=)
CN (2) CN113413387A (https=)
AU (3) AU2016262459A1 (https=)
BR (1) BR112017024253A2 (https=)
CA (1) CA2984480A1 (https=)
EA (1) EA201792496A1 (https=)
HK (1) HK1252658A1 (https=)
IL (2) IL255239A0 (https=)
MX (2) MX2017014344A (https=)
SG (1) SG10202012002TA (https=)
WO (1) WO2016183097A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
KR20190085046A (ko) * 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) * 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL297470A (en) * 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
US12599600B2 (en) * 2020-05-29 2026-04-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN119031909A (zh) * 2022-03-31 2024-11-26 梅约医学教育与研究基金会 用于治疗胰腺疾病和病症的方法和材料
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (https=) 1967-10-17 1970-06-01
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
WO1993011097A1 (en) 1991-11-27 1993-06-10 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO1995017439A2 (en) 1993-12-22 1995-06-29 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
TW200531694A (en) 2004-02-18 2005-10-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
WO2011054795A1 (de) 2009-11-03 2011-05-12 Bayer Materialscience Ag Fluorurethane als additive in einer photopolymer-formulierung
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
EP2828253A1 (en) * 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
LT3470063T (lt) 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Similar Documents

Publication Publication Date Title
JP2018515460A5 (https=)
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
CN110352188A (zh) 氟代烯丙胺衍生物及其用途
JP2020502047A5 (https=)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2014114305A5 (https=)
JP2015508749A5 (https=)
JP2015120736A5 (https=)
JP2017505285A5 (https=)
CN115315427A (zh) Hpk1抑制剂及其制备方法和用途
JP2017520613A5 (https=)
JP2019516739A5 (https=)
CN110891953A (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
CN110072865A (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
JP2017538712A5 (https=)
CN115315423A (zh) 取代芳基类化合物
JP2016522254A5 (https=)
CN111566100A (zh) 嘧啶类化合物、其制备方法及其医药用途
JP2018145180A5 (https=)
CN113905735A (zh) 神经激肽-1拮抗剂
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2021000904A (es) Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada.
CN109563082A (zh) 核磁共振显像化合物、其中间体、核磁共振显像剂及应用、以及核磁共振成像方法
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物
JP2007530703A5 (https=)